Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 4/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | PNP | P00491 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23168969 | 0.88 | MAPT (0.38) | NPBWR1MAPK14 | |
| SCHEMBL23168645 | 0.81 | ALDH1A1 (0.42) | NPBWR1MAPK14P2RX7 | |
| SCHEMBL24820993 | 0.81 | MKNK1 (0.42) | NPBWR1MAPK14 | |
| SCHEMBL23168624 | 0.79 | BRD4 (0.42) | NPBWR1P2RX7 | |
| SCHEMBL29821664 | 0.73 | SOS1 (0.43) | GAA | |
| SCHEMBL24449327 | 0.73 | NPBWR1 (0.36) | NPBWR1 | |
| SCHEMBL23168928 | 0.72 | THRB (0.38) | NPBWR1 | |
| SCHEMBL11170879 | 0.72 | HPGD (0.47) | MAPK14GAA | |
| SCHEMBL29821419 | 0.70 | MAPT (0.51) | NPBWR1P2RX7 | |
| SCHEMBL23168940 | 0.70 | MAPT (0.40) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617769-B2 | Chemical compound as thyroid hormone beta receptor agonist and use thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2026-05-05 | — | — | US | disclosed |
| US-20220411400-A1 | CHEMICAL COMPOUND AS THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-12-29 | — | — | US | disclosed |
| EP-4036090-A1 | CHEMICAL COMPOUND AS THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2022-08-03 | — | — | EP | disclosed |
| WO-2021057791-A1 | CHEMICAL COMPOUND AS THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF | 广东东阳光药业有限公司 | 2021-04-01 | — | — | WO | disclosed |
| WO-2021057791-A1 | CHEMICAL COMPOUND AS THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF | 广东东阳光药业有限公司 | 2021-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411400-A1 | CHEMICAL COMPOUND AS THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF | THRB, TSHR, THRA | NPBWR1 336/4885MAPK14 2227/4885P2RX7 1050/4885 |
| US-12617769-B2 | Chemical compound as thyroid hormone beta receptor agonist and use thereof | THRB, TSHR, THRA | NPBWR1 267/4885MAPK14 3984/4885P2RX7 2319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.